Zoledronic acid and atrial fibrillation in cancer patients

ARSLAN Ç., AKSOY S., DİZDAR Ö., Dede D. S., HARPUTLUOĞLU H., ALTUNDAĞ M. K.

SUPPORTIVE CARE IN CANCER, cilt.19, sa.3, ss.425-430, 2011 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 19 Sayı: 3
  • Basım Tarihi: 2011
  • Doi Numarası: 10.1007/s00520-010-0868-z
  • Dergi Adı: SUPPORTIVE CARE IN CANCER
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.425-430
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Treatment with a bisphosphonate was found to be associated with a significantly increased risk for atrial fibrillation (AF) in a few studies. A recent study showed that once-yearly infusions of intravenous zoledronic acid (ZA) significantly increased the risk of serious AF in postmenopausal women with osteoporosis. This study was conducted to determine the frequency of atrial fibrillation among cancer patients receiving the standard treatment of ZA.